Trials / Completed

CompletedNCT05164016

Evaluating Immune Response to COVID-19 Vaccines in Patients With Cancer, Transplant or Cellular Therapy Recipients

Status: Completed
Phase: —
Study type: Observational
Enrollment: 21 (actual)

Sponsor: St. Jude Children's Research Hospital · Academic / Other
Sex: All
Age: 24 Years
Healthy volunteers: Not accepted

Summary

This study is being done because the investigators would like to learn more about how well the COVID-19 vaccine works in participants with cancer or those who have received a transplant or cellular therapy. Primary Objective Assess the immunogenicity to COVID-19 vaccination in patients with cancer and/or transplant and cellular therapy (TCT) recipients. Secondary Objectives * Evaluate the antibodies response to COVID-19 vaccination in immunocompromised patients. * Evaluate the T cell response to COVID-19 vaccination in immunocompromised patients. Exploratory Objectives * Assess incidence and severity of COVID-19 infections by 6 months following immunization with a SARS CoV-2 vaccine. * Assess the durability immune response to COVID-19 vaccination. * Assess the immunogenicity of COVID-19 vaccination in immunocompetent children and adolescents without cancer and have not undergone transplant or received cellular therapy.

Detailed description

The investigator will collect a blood sample (about 1 teaspoon each time) from the participant when the participant receive the COVID-19 vaccine(s) as well as an additional blood samples 6 months after the last COVID-19 vaccine. The participant will be on the study for about 6 months after the last vaccine. After the six-month blood sample is collected, the participant will be off study.

Conditions

Timeline

Start date: 2022-06-29
Primary completion: 2025-05-01
Completion: 2026-04-09
First posted: 2021-12-20
Last updated: 2026-04-15

Locations

3 sites across 1 country: United States

Source: ClinicalTrials.gov record NCT05164016. Inclusion in this directory is not an endorsement.